6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- Resource Type
- Article
- Source
- The Lancet; June-July 2019, Vol. 393 Issue: 10191 p2599-2612, 14p
- Subject
- Language
- ISSN
- 01406736; 1474547X